Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Better Buy: Pfizer vs. GlaxoSmithKline

TheMotleyFool

0 0

Better Buy: Pfizer vs. GlaxoSmithKlinePhoto, wide shot, wide-angle lens, Clinical research organization, sunset photo at golden hour, photo by Peter Lik: https://img.midjourneyapi.xyz/temp/02f7778c-d723-4fb3-bdef-fabb7e5fc9c8.png

Pharma giants Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) share similar visions for the future. Both aim to transform into smaller, nimbler biopharmaceutical outfits focused on high-value R&D. Last year, investors witnessed the strategy begin to take shape at both businesses.

Image source: Getty Images.

In August 2019, Pfizer and Glaxo completed the combination of their consumer healthcare businesses into a new joint venture. The unit operates under the GSK Consumer Healthcare name, with Glaxo holding a 68% majority stake. The operation boasts the largest global portfolio of over-the-counter medicines, vitamins, minerals, and supplements.

Source Fool.com

Like: 0

PFE

Teilen